MCID: KPS004
MIFTS: 67

Kaposi Sarcoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Blood diseases, Neuronal diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 54 12 50 56 52 69
Kaposi's Sarcoma 12 50 41 14
Angiofollicular Ganglionic Hyperplasia 56 69
Kaposi's Sarcoma of Soft Tissue 12 69
Kaposi's Sarcoma of Palate 12 69
Kaposi's Sarcoma of Lung 12 69
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Multicentric Giant Lymph Node Hyperplasia 56
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Lymphadenopathic Kaposi's Sarcoma 12
Angiofollicular Lymph Hyperplasia 56
Kaposi Sarcoma, Susceptibility to 13
Multi-Centric Castleman's Disease 69
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 50
Non-Aids-Related Kaposi Sarcoma 69
Multicentric Castleman Disease 56
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 50
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 50
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 69
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 50
Castleman Disease 56
Sarcoma, Kaposi 42
Hhv8 50
Kshv 50
Mcd 56

Characteristics:

Orphanet epidemiological data:

56
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 50 kaposi sarcoma (ks) is a cancer that develops from the cells that line lymph or blood vessels. it usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). the abnormal cells of kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. these lesions may look bad, but they usually cause no symptoms. however, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. kaposi sarcoma is caused by infection with a virus called the kaposi sarcoma associated herpesvirus (kshv), also known as human herpesvirus 8 (hhv8). kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-saharan indigenous africans), iatrogenic (associated with immunosuppressive drug therapy) and aids-associated (epidemic ks). options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). the main aim is to restore immunity. last updated: 2/4/2016

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to lichen planus and actinomycosis, and has symptoms including diarrhea, fatigue and encephalopathy. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Doxil and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and lymph node, and related phenotypes are hematopoietic system and cellular

MedlinePlus : 41 kaposi's sarcoma (ks) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. these patches, or lesions, are usually red or purple. they are made of cancer cells, blood vessels, and blood cells. ks is caused by infection with human herpesvirus-8 (hhv-8). most people infected with hhv-8 don't get ks. it usually happens in people with weak immune systems, due to hiv/aids, drugs taken after an organ transplant, or another disease older men of jewish or mediterranean descent young men in africa the skin lesions may not cause symptoms. but they can spread to other parts of the body, especially in people with hiv/aids. if they spread to the digestive tract or lungs, they can cause bleeding. lesions on the lungs can also make it hard to breathe. treatment depends on where the lesions are and how bad they are. options include radiation therapy, surgery, chemotherapy, and biologic therapy. people with hiv/aids also take hiv/aids medicines. nih: national cancer institute

OMIM : 54
Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results_in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
id Related Disease Score Top Affiliating Genes
1 lichen planus 30.6 FGF2 ICAM1 IL6 VEGFA
2 actinomycosis 30.0 IFNA1 IFNB1 IRF3 IRF7
3 rheumatoid arthritis 29.7 CXCL1 ICAM1 IL6 IL6ST VEGFA
4 angiofollicular lymph hyperplasia 12.2
5 endemic kaposi sarcoma 12.2
6 colon kaposi sarcoma 11.9
7 immunodeficiency 16 11.7
8 malonyl-coa decarboxylase deficiency 11.7
9 multiple carboxylase deficiency 11.6
10 macular corneal dystrophy 11.6
11 human herpesvirus 8 11.4
12 unicentric castleman disease 11.2
13 rectum kaposi's sarcoma 11.0
14 localized anterior staphyloma 11.0 IFNA1 TP53
15 sarcoma 10.9
16 hyperinsulinism due to short chain 3-hydroxylacyl-coa dehydrogenase deficiency 10.9 IFNA1 IFNB1
17 hyperaldosteronism 10.9 ICAM1 IL6 VEGFA
18 focal dystonia 10.8 FGF2 IL6 VEGFA
19 urinary bladder posterior wall cancer 10.8 FGF2 IL6 VEGFA
20 male infertility 10.8 IFNA1 IFNA2
21 renal fibrosis 10.8 FGF2 IL6 VEGFA
22 breast ductal adenoma 10.8 IFNA1 IFNA2
23 neuropathy, hereditary sensory and autonomic, type vi 10.8 FGF2 ICAM1 VEGFA
24 trachea carcinoma in situ 10.8 IL6 IL6ST TP53 VEGFA
25 periampullary adenoma 10.8 ICAM1 IL6 VEGFA
26 non-suppurative otitis media 10.8 IFNA1 IFNB1 TP53
27 endometriosis of uterus 10.7 FGF2 TP53 VEGFA
28 acral lentiginous melanoma 10.7 IFNA1 IFNA2 IL6 TP53
29 dubin-johnson syndrome 10.7 CDK6 IFNA2 TP53
30 zimmermann-laband syndrome 2 10.7 CDK6 FGF2 TP53 VEGFA
31 cutaneous leishmaniasis 10.7 IL6 VEGFA
32 neonatal jaundice 10.7 ICAM1 IFNA1 IFNB1 IL6
33 citrullinemia, adult-onset type ii 10.7 FGF2 ICAM1 VEGFA
34 bronchiolitis 10.7 IFNA1 IFNB1 IRF3
35 esophagus lymphoma 10.7 IFNA2 IL6 TP53 VEGFA
36 pulmonary tuberculosis 10.6 IFNA1 IFNB1 IRF3
37 crohn disease-associated growth failure 10.6 IL6 VEGFA
38 advanced sleep phase syndrome, familial, 1 10.6 ICAM1 IFNA1 IFNB1 IL6
39 ovarian brenner tumor 10.6 FGF2 IFNA1 IFNA2 TP53 VEGFA
40 gallbladder cancer 10.6 IL6 TP53 VEGFA
41 purulent endophthalmitis 10.6 FGF2 PDGFB VEGFA
42 glycogen storage disease due to lactate dehydrogenase deficiency 10.5 CASP8 TP53
43 secretory diarrhea 10.5 CXCL1 IFNB1 IRF3
44 optic nerve hypoplasia 10.4 CXCL1 FGF2 IL6
45 nail disorder, nonsyndromic congenital, 1 10.4 FGF2 TP53 VEGFA
46 gestational choriocarcinoma 10.4 FGF2 PDGFB TP53 VEGFA
47 eczematous dermatitis of eyelid 10.4 IFNA1 IFNA2 IFNB1 IRF3 IRF7
48 glomus vagale tumor 10.3 CDK6 FGF2 PDGFB TP53
49 lymphoma 10.3
50 castleman disease 10.3

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Symptoms via clinical synopsis from OMIM:

54

Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema


Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

56 32 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diarrhea 56 32 occasional (7.5%) Occasional (29-5%) HP:0002014
2 fatigue 56 32 occasional (7.5%) Occasional (29-5%) HP:0012378
3 encephalopathy 56 32 frequent (33%) Frequent (79-30%) HP:0001298
4 immunodeficiency 56 32 frequent (33%) Frequent (79-30%) HP:0002721
5 hemangioma 56 32 frequent (33%) Frequent (79-30%) HP:0001028
6 fever 56 32 occasional (7.5%) Occasional (29-5%) HP:0001945
7 weight loss 56 32 occasional (7.5%) Occasional (29-5%) HP:0001824
8 skin rash 56 32 occasional (7.5%) Occasional (29-5%) HP:0000988
9 lymphedema 56 32 occasional (7.5%) Occasional (29-5%) HP:0001004
10 generalized lymphadenopathy 56 32 frequent (33%) Frequent (79-30%) HP:0008940
11 abnormality of the spleen 56 32 frequent (33%) Frequent (79-30%) HP:0001743
12 neoplasm of the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0008069
13 abnormality of lung morphology 56 32 occasional (7.5%) Occasional (29-5%) HP:0002088
14 venous insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0005293
15 hypermelanotic macule 56 32 hallmark (90%) Very frequent (99-80%) HP:0001034
16 papule 56 32 frequent (33%) Frequent (79-30%) HP:0200034
17 abnormality of the gastrointestinal tract 56 32 frequent (33%) Frequent (79-30%) HP:0011024
18 abnormality of the liver 56 32 occasional (7.5%) Occasional (29-5%) HP:0001392
19 abnormality of the lower limb 56 32 hallmark (90%) Very frequent (99-80%) HP:0002814
20 abnormality of the retina 56 32 frequent (33%) Frequent (79-30%) HP:0000479
21 skin nodule 56 32 frequent (33%) Frequent (79-30%) HP:0200036
22 skin plaque 56 32 occasional (7.5%) Occasional (29-5%) HP:0200035
23 susceptibility to herpesvirus 56 32 obligate (100%) Obligate (100%) HP:0005353
24 lymphoproliferative disorder 56 32 frequent (33%) Frequent (79-30%) HP:0005523
25 edema 32 HP:0000969
26 neoplasm 32 HP:0002664
27 macule 56 Very frequent (99-80%)
28 neoplasm by anatomical site 56 Occasional (29-5%)

UMLS symptoms related to Kaposi Sarcoma:


exanthema, pruritus, fever

MGI Mouse Phenotypes related to Kaposi Sarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CASP8 CCR3 CDK6 FGF2 ICAM1 IFNB1
2 cellular MP:0005384 10.21 CASP8 CCR3 CDK6 FGF2 FGF4 ICAM1
3 homeostasis/metabolism MP:0005376 10.18 CCR3 FGF2 ICAM1 IFNB1 IL6 IL6ST
4 immune system MP:0005387 10.17 TP53 VEGFA CASP8 CCR3 CCR8 CDK6
5 liver/biliary system MP:0005370 9.8 CASP8 CDK6 IL6 IL6ST PDGFB TP53
6 muscle MP:0005369 9.76 CASP8 CDK6 FGF2 ICAM1 IL6 PDGFB
7 neoplasm MP:0002006 9.65 CASP8 CDK6 FGF2 ICAM1 IFNB1 IL6
8 vision/eye MP:0005391 9.23 IL6ST PDGFB SLC7A11 TP53 VEGFA FGF2

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
5
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
7
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
12
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
14 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
21 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
23 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
25 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
26 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
27 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
28
Tenofovir Phase 4,Phase 3 147127-20-6 464205
29 Ganciclovir triphosphate Phase 4,Phase 2
30
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
33
Zidovudine Approved Phase 2, Phase 3, Phase 1 30516-87-1 35370
34
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
35
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
36
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Analgesics Phase 3,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1
47 Cyclooxygenase 2 Inhibitors Phase 3
48 Cyclooxygenase Inhibitors Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Albumin-Bound Paclitaxel Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 160)

id Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
4 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
8 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
9 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
10 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
11 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
13 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
14 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
16 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Recruiting NCT01435018 Phase 3 Coformulated EFV/FTC/TDF;Etoposide;Bleomycin and Vincristine (BV);Paclitaxel (PTX)
17 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
18 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Active, not recruiting NCT01924286 Phase 3 Prednisone;Placebo
19 A Study of Selumetinib in Patients With Kaposi's Sarcoma Unknown status NCT01752569 Phase 1, Phase 2 Selumetinib
20 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
21 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
22 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
23 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
24 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
25 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
26 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
27 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
28 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
29 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
30 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
31 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
32 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
33 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma Completed NCT00019123 Phase 2 thalidomide
34 Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2 indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate
35 Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection Completed NCT00019240 Phase 2 cidofovir
36 Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00020449 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
37 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
38 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
39 Suppression of Oral HHV8 Shedding With Valganciclovir Completed NCT00194467 Phase 2 valganciclovir;placebo
40 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002188 Phase 2 Alitretinoin
41 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
42 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
43 The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
44 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
45 SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment Completed NCT00005931 Phase 2 SU5416
46 The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2 Interferon alfa-2b;Didanosine
47 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin
48 A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma Completed NCT00002314 Phase 2 Ro 24-7429
49 A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00000996 Phase 2 Doxorubicin hydrochloride
50 Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Completed NCT00002189 Phase 2 Paclitaxel

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

39
Skin, Lung, Lymph Node, Prostate, Liver, Heart, T Cells

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 379)
id Title Authors Year
1
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden. ( 28662221 )
2017
2
Kaposi Sarcoma and Lung Transplant: Two Case Reports. ( 28501344 )
2017
3
Oral Kaposi Sarcoma in HIV-seronegative Saudi patient: Literature review and case report. ( 28725131 )
2017
4
Is acquired arterial-venous fistula related to Kaposi sarcoma? ( 28214029 )
2017
5
Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. ( 28531260 )
2017
6
Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. ( 28829790 )
2017
7
Nonepidemic Kaposi sarcoma: A recently proposed category. ( 28913409 )
2017
8
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. ( 28341759 )
2017
9
Kaposi Sarcoma in an Human Immunodeficiency Virus (HIV)-Seronegative Mediterranean Female: Report of a Rare Case. ( 28743856 )
2017
10
Diagnosis and Treatment of Kaposi Sarcoma. ( 28324233 )
2017
11
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. ( 28046107 )
2017
12
Treatment of cutaneous iatrogenic Kaposi sarcoma with topical timolol. ( 28853153 )
2017
13
Epigenetic manipulation of host chromatin by Kaposi sarcoma-associated herpesvirus: a tumor-promoting factor? ( 28802146 )
2017
14
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report. ( 28329475 )
2017
15
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. ( 28881567 )
2017
16
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
17
Oral Localization of Kaposi Sarcoma: Clinical Presentation and Conservative Management. ( 28708648 )
2017
18
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
19
BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. ( 28404899 )
2017
20
Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. ( 28649271 )
2017
21
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. ( 28430817 )
2017
22
Topical timolol for treatment of penile Kaposi sarcoma in HIV-negative patient. ( 28677301 )
2017
23
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. ( 28216610 )
2017
24
Lymphangioma-like classic Kaposi sarcoma. ( 28188608 )
2017
25
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. ( 28087020 )
2017
26
Successful Treatment of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations With the Human Herpesvirus 8 miRNome and Specific T Cell Response. ( 28489271 )
2017
27
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
28
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. ( 28157730 )
2017
29
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
30
Acquired Immune Deficiency Syndrome-Associated Kaposi Sarcoma in a Child Presenting as a Solitary Plantar Hyperkeratotic Plaque. ( 28288525 )
2017
31
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. ( 28424322 )
2017
32
Kaposi Sarcoma in a patient treated with Ruxolitinib. ( 28419187 )
2017
33
Topical diphencyprone for Kaposi sarcoma. ( 28133860 )
2017
34
Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. ( 27986137 )
2017
35
Murine Gammaherpesvirus 68 Expressing Kaposi Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen (LANA) Reveals both Functional Conservation and Divergence in LANA Homologs. ( 28747501 )
2017
36
Pulmonary Kaposi sarcoma presenting as complete lung consolidation. ( 28331023 )
2017
37
Kaposi sarcoma: An unconventional cause of lower extremity lymphedema. ( 28875759 )
2017
38
Recombinant parvoviruses armed to deliver CXCL4L1 and CXCL10 are impaired in their antiangiogenic and antitumoral effects in a Kaposi sarcoma tumor model due to the chemokines' interference with the virus cycle. ( 28042949 )
2017
39
Hepatic Kaposi sarcoma: A case report and review of the literature. ( 28217255 )
2017
40
Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. ( 28077522 )
2017
41
Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. ( 28845155 )
2017
42
Ultraviolet Radiation and Kaposi Sarcoma Incidence in a Nationwide US Cohort of HIV-Infected Men. ( 28040691 )
2017
43
The pattern of secondary cancers in patients with Kaposi sarcoma in the United States. ( 28900786 )
2017
44
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden-Reply. ( 28662223 )
2017
45
mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi Sarcoma. ( 28506734 )
2017
46
Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy. ( 28837714 )
2017
47
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. ( 28488400 )
2017
48
An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus. ( 28872106 )
2017
49
Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. ( 28865422 )
2017
50
Kaposi sarcoma herpesvirus pathogenesis. ( 28893942 )
2017

Variations for Kaposi Sarcoma

Cosmic variations for Kaposi Sarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 64
2 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 64
3 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 5
4 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 5

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CASP8 CXCL1 FGF2 FGF4 ICAM1 IFNA1
2
Show member pathways
13.89 CASP8 CCR3 CCR8 CDK6 CXCL1 FGF2
3
Show member pathways
13.88 CASP8 FGF2 FGF4 IFNA1 IFNA2 IFNB1
4
Show member pathways
13.62 CASP8 CCR3 CCR8 CXCL1 IFNA1 IFNA2
5
Show member pathways
13.56 FGF2 FGF4 ICAM1 IFNA1 IFNA2 IFNB1
6
Show member pathways
13.44 CCR3 CCR8 CXCL1 FGF2 FGF4 IL6
7
Show member pathways
13.33 CASP8 CCR3 CCR8 CXCL1 FGF2 FGF4
8
Show member pathways
13.33 IFNA1 IFNA2 IFNB1 IRF3 IRF7 PDGFB
9
Show member pathways
12.99 CASP8 CXCL1 IFNA1 IFNA2 IFNB1 IL6
10
Show member pathways
12.91 CXCL1 FGF2 FGF4 ICAM1 IFNA1 IFNA2
11
Show member pathways
12.89 CASP8 ICAM1 IFNA1 IFNA2 IL6 VEGFA
12
Show member pathways
12.89 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
13
Show member pathways
12.74 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
14 12.73 CASP8 FGF2 FGF4 PDGFB TP53
15 12.63 CASP8 CDK6 FGF2 FGF4 IL6 PDGFB
16
Show member pathways
12.62 CXCL1 FGF2 IL6 PDGFB TP53
17
Show member pathways
12.58 CDK6 FGF2 FGF4 IL6 PDGFB TP53
18
Show member pathways
12.56 ICAM1 IFNA1 IFNA2 IFNB1 IRF3 IRF7
19
Show member pathways
12.55 CASP8 CDK6 ICAM1 IFNA1 IFNA2 IFNB1
20 12.43 ICAM1 IL6 PDGFB TP53
21
Show member pathways
12.34 CASP8 CXCL1 IL6 IL6ST
22
Show member pathways
12.32 IFNA1 IFNA2 IFNB1 IL6
23 12.27 CASP8 IFNA1 IFNA2 IFNB1 IL6
24
Show member pathways
12.25 IFNA1 IFNA2 IFNB1 IL6 IL6ST
25 12.17 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
26 12.16 CASP8 CCR3 CCR8 CDK6 IL6ST IRF3
27
Show member pathways
12.14 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
28 12.12 ICAM1 PDGFB TP53 VEGFA
29 12.1 FGF2 FGF4 IL6 PDGFB VEGFA
30 12.07 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
31 12.05 CXCL1 ICAM1 IL6 TP53
32 11.99 CASP8 CXCL1 ICAM1 IL6
33 11.99 FGF2 ICAM1 IL6 TP53 VEGFA
34 11.94 CASP8 CDK6 FGF2 FGF4 IFNA1 IFNA2
35 11.93 FGF2 FGF4 IL6 PDGFB
36 11.93 IFNA1 IFNA2 IFNB1 IL6 IL6ST
37
Show member pathways
11.91 CXCL1 ICAM1 IL6 IL6ST
38 11.89 CXCL1 ICAM1 IL6 VEGFA
39 11.87 CXCL1 IFNB1 IL6 IL6ST IRF7 TP53
40 11.83 FGF2 FGF4 PDGFB VEGFA
41 11.8 ICAM1 IL6 TP53
42 11.77 IFNA2 IFNB1 IL6
43 11.71 CCR3 FGF2 IL6 PDGFB
44
Show member pathways
11.68 ICAM1 IL6 VEGFA
45 11.61 CASP8 CXCL1 IL6
46 11.58 IL6 TP53 VEGFA
47 11.56 CXCL1 ICAM1 IL6
48 11.52 CASP8 FGF2 VEGFA
49 11.48 FGF2 FGF4 IL6 PDGFB VEGFA
50 11.42 ICAM1 IFNA2 IFNB1

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CXCL1 FGF2 FGF4 IFNA1 IFNA2 IFNB1
2 extracellular space GO:0005615 9.61 CXCL1 FGF2 ICAM1 IFNA1 IFNA2 IFNB1
3 interleukin-6 receptor complex GO:0005896 8.62 IL6 IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 47)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 CDK6 FGF4 IL6 PDGFB TP53 VEGFA
2 chemotaxis GO:0006935 9.96 CCR3 CCR8 CXCL1 FGF2
3 cytokine-mediated signaling pathway GO:0019221 9.95 IFNA1 IFNA2 IL6 IL6ST
4 defense response GO:0006952 9.95 CXCL1 IFNA1 IFNA2 IFNB1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 FGF2 FGF4 ICAM1 IL6 PDGFB
6 phosphatidylinositol-mediated signaling GO:0048015 9.89 FGF2 FGF4 PDGFB TP53
7 response to lipopolysaccharide GO:0032496 9.88 CASP8 CXCL1 ICAM1 IL6 IRF3
8 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.87 FGF2 FGF4 PDGFB
9 viral process GO:0016032 9.87 CASP8 CCR3 ICAM1 IL6ST IRF3 IRF7
10 chemokine-mediated signaling pathway GO:0070098 9.86 CCR3 CCR8 CXCL1
11 interferon-gamma-mediated signaling pathway GO:0060333 9.86 ICAM1 IRF3 IRF7
12 B cell differentiation GO:0030183 9.85 IFNA1 IFNA2 IFNB1
13 positive regulation of MAP kinase activity GO:0043406 9.85 FGF2 PDGFB VEGFA
14 positive chemotaxis GO:0050918 9.82 FGF2 PDGFB VEGFA
15 response to antibiotic GO:0046677 9.8 CASP8 IL6 TP53
16 cellular response to dexamethasone stimulus GO:0071549 9.8 ICAM1 IFNB1 IL6
17 B cell proliferation GO:0042100 9.79 IFNA1 IFNA2 IFNB1
18 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.76 CASP8 IRF3 IRF7
19 positive regulation of endothelial cell proliferation GO:0001938 9.76 CCR3 FGF2 PDGFB VEGFA
20 regulation of type I interferon-mediated signaling pathway GO:0060338 9.75 IFNA1 IFNA2 IFNB1
21 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 FGF2 PDGFB VEGFA
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNA2 IL6 IL6ST VEGFA
23 T cell activation involved in immune response GO:0002286 9.72 IFNA1 IFNA2 IFNB1
24 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.71 IFNA1 IFNA2 IFNB1
25 humoral immune response GO:0006959 9.71 IFNA1 IFNA2 IFNB1 IL6
26 positive regulation of interferon-alpha production GO:0032727 9.7 IRF3 IRF7
27 cellular response to nutrient levels GO:0031669 9.7 ICAM1 IL6
28 natural killer cell activation involved in immune response GO:0002323 9.7 IFNA1 IFNA2 IFNB1
29 positive regulation of acute inflammatory response GO:0002675 9.69 IL6 IL6ST
30 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.69 IRF3 IRF7
31 interleukin-6-mediated signaling pathway GO:0070102 9.68 IL6 IL6ST
32 negative regulation of T cell differentiation GO:0045581 9.67 IFNA2 IFNB1
33 cellular response to dsRNA GO:0071359 9.67 IFNB1 IRF3
34 positive regulation of cell division GO:0051781 9.67 FGF2 FGF4 PDGFB VEGFA
35 chondroblast differentiation GO:0060591 9.66 FGF2 FGF4
36 type I interferon biosynthetic process GO:0045351 9.64 IRF3 IRF7
37 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.61 FGF2 FGF4
38 MDA-5 signaling pathway GO:0039530 9.61 IRF3 IRF7
39 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.6 IFNA2 IFNB1
40 response to exogenous dsRNA GO:0043330 9.56 IFNA1 IFNA2 IFNB1 IRF3
41 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.55 ICAM1 IL6 PDGFB TP53 VEGFA
42 defense response to virus GO:0051607 9.43 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
43 type I interferon signaling pathway GO:0060337 9.02 IFNA1 IFNA2 IFNB1 IRF3 IRF7
44 positive regulation of transcription, DNA-templated GO:0045893 10.13 FGF2 IFNA2 IL6 IRF7 PDGFB TP53
45 positive regulation of cell proliferation GO:0008284 10.11 FGF2 FGF4 IL6 IL6ST PDGFB VEGFA
46 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.11 FGF2 FGF4 IFNB1 IL6 IRF7 TP53
47 negative regulation of apoptotic process GO:0043066 10.1 FGF4 IL6 IL6ST TP53 VEGFA

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 FGF2 FGF4 PDGFB
2 chemoattractant activity GO:0042056 9.5 FGF2 PDGFB VEGFA
3 C-C chemokine receptor activity GO:0016493 9.43 CCR3 CCR8
4 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
5 growth factor activity GO:0008083 9.43 CXCL1 FGF2 FGF4 IL6 PDGFB VEGFA
6 interleukin-6 receptor binding GO:0005138 9.37 IL6 IL6ST
7 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
8 cytokine activity GO:0005125 9.17 CXCL1 FGF2 IFNA1 IFNA2 IFNB1 IL6

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....